MedTrace Logo

MESS-study MRSA Eradication Study Skåne

NCT01269541 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2017-08-22

No results posted yet for this study

Summary

The purpose of this study is to determine whether systemic antibiotic treatment with rifampicin and clindamycine or trimethoprim-sulfa in addition to topical treatment with mupirocin is more effective than only topical treatment to eradicate MRSA in throatcarriers

Conditions

  • Throatcarriers of MRSA

Interventions

DRUG

Mupirocin

Topical in the nose 3 times daily for 5 days

DRUG

Rifampin+Clindamycine or Trimehoprimsulfa

Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3 Trimethoprimsulfa 400mg/80mg 2x2

Sponsors & Collaborators

  • Region Skane

    lead OTHER

Principal Investigators

  • Eva Melander, MD PHD · Labmedicin Skåne Malmö

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-01
Primary Completion
2015-05-01
Completion
2015-05-01

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01269541 on ClinicalTrials.gov